These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30199301)

  • 1. Oral corticosteroid exposure and increased risk of related complications in patients with noninfectious intermediate, posterior, or panuveitis: Real-world data analysis.
    Chirikov VV; Shah R; Kwon Y; Patel D
    Ophthalmic Epidemiol; 2019 Feb; 26(1):27-46. PubMed ID: 30199301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials.
    Suhler EB; Thorne JE; Mittal M; Betts KA; Tari S; Camez A; Bao Y; Joshi A
    Ophthalmology; 2017 Dec; 124(12):1799-1807. PubMed ID: 28689898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.
    Sheppard J; Joshi A; Betts KA; Hudgens S; Tari S; Chen N; Skup M; Dick AD
    JAMA Ophthalmol; 2017 Jun; 135(6):511-518. PubMed ID: 28426849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.
    ; Kempen JH; Altaweel MM; Drye LT; Holbrook JT; Jabs DA; Sugar EA; Thorne JE
    Ophthalmology; 2015 Oct; 122(10):1967-75. PubMed ID: 26298715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Two-Year Results.
    Jaffe GJ; Lin P; Keenan RT; Ashton P; Skalak C; Stinnett SS
    Ophthalmology; 2016 Sep; 123(9):1940-8. PubMed ID: 27421623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study.
    Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group
    Ophthalmology; 2015 Oct; 122(10):1976-86. PubMed ID: 26298718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
    Suhler EB; Jaffe GJ; Fortin E; Lim LL; Merrill PT; Dick AD; Brezin AP; Nguyen QD; Thorne JE; Van Calster J; Cimino L; Adan A; Goto H; Kaburaki T; Kramer M; Vitale AT; Kron M; Song AP; Liu J; Pathai S; Douglas KM; Schlaen A; Muccioli C; Van Velthoven MEJ; Zierhut M; Rosenbaum JT
    Ophthalmology; 2021 Jun; 128(6):899-909. PubMed ID: 33157077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial.
    ; Kempen JH; Altaweel MM; Holbrook JT; Jabs DA; Louis TA; Sugar EA; Thorne JE
    Ophthalmology; 2011 Oct; 118(10):1916-26. PubMed ID: 21840602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
    Al-Janabi A; El Nokrashy A; Sharief L; Nagendran V; Lightman S; Tomkins-Netzer O
    Ophthalmology; 2020 Mar; 127(3):410-416. PubMed ID: 31607412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series.
    Nussenblatt RB; Peterson JS; Foster CS; Rao NA; See RF; Letko E; Buggage RR
    Ophthalmology; 2005 May; 112(5):764-70. PubMed ID: 15878055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal Vision-Related Quality of Life for Patients with Noninfectious Uveitis Treated with Fluocinolone Acetonide Implant or Systemic Corticosteroid Therapy.
    Sugar EA; Venugopal V; Thorne JE; Frick KD; Holland GN; Wang RC; Almanzor R; Jabs DA; Holbrook JT;
    Ophthalmology; 2017 Nov; 124(11):1662-1669. PubMed ID: 28624167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III.
    Suhler EB; Adán A; Brézin AP; Fortin E; Goto H; Jaffe GJ; Kaburaki T; Kramer M; Lim LL; Muccioli C; Nguyen QD; Van Calster J; Cimino L; Kron M; Song AP; Liu J; Pathai S; Camez A; Schlaen A; van Velthoven MEJ; Vitale AT; Zierhut M; Tari S; Dick AD
    Ophthalmology; 2018 Jul; 125(7):1075-1087. PubMed ID: 29429764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
    Dick AD; Tundia N; Sorg R; Zhao C; Chao J; Joshi A; Skup M
    Ophthalmology; 2016 Mar; 123(3):655-62. PubMed ID: 26712559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis: Evolution through Preclinical and Clinical Studies.
    Nguyen QD; Merrill PT; Sepah YJ; Ibrahim MA; Banker A; Leonardi A; Chernock M; Mudumba S; Do DV
    Ophthalmology; 2018 Dec; 125(12):1984-1993. PubMed ID: 30060978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and Outcome of Uveitic Glaucoma in Eyes With Intermediate, Posterior, or Panuveitis Followed up to 10 Years After Randomization to Fluocinolone Acetonide Implant or Systemic Therapy.
    Kempen JH; Van Natta ML; Friedman DS; Altaweel MM; Ansari H; Dunn JP; Elner SG; Holbrook JT; Lim LL; Sugar EA; Jabs DA;
    Am J Ophthalmol; 2020 Nov; 219():303-316. PubMed ID: 32628922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Experience with Anti-tumor Necrosis factor - α Therapy in the Treatment of Refractory, Non-infectious Intermediate, Posterior, and Panuveitis.
    Corredores Dieb J; Vofo B; Amer R
    Ocul Immunol Inflamm; 2024 Aug; 32(6):932-939. PubMed ID: 36538811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to disease recurrence in noninfectious uveitis following long-acting injectable fluocinolone acetonide implant.
    Cai CX; Skalak C; Keenan RT; Grewal DS; Jaffe GJ
    Graefes Arch Clin Exp Ophthalmol; 2020 May; 258(5):1023-1030. PubMed ID: 32114654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of Treating Pediatric Uveitis With Dexamethasone Implants.
    Tomkins-Netzer O; Talat L; Seguin-Greenstein S; Bar A; Lightman S
    Am J Ophthalmol; 2016 Jan; 161():110-5.e1-2. PubMed ID: 26478217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of uveitis presenting for the first time in the elderly: analysis of 91 patients in a tertiary center.
    Grégoire MA; Kodjikian L; Varron L; Grange JD; Broussolle C; Seve P
    Ocul Immunol Inflamm; 2011 Aug; 19(4):219-26. PubMed ID: 21770796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality-of-Life Outcomes From a Randomized Clinical Trial Comparing Antimetabolites for Intermediate, Posterior, and Panuveitis.
    Niemeyer KM; Gonzales JA; Rathinam SR; Babu M; Thundikandy R; Kanakath A; Porco TC; Browne EN; Rao MM; Acharya NR
    Am J Ophthalmol; 2017 Jul; 179():10-17. PubMed ID: 28414043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.